Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN ... Financial Post The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company's overall ... |
